A Review of the Rational and Current Evidence on Colchicine for COVID-19

被引:3
|
作者
Ghaith, Hazem S. [1 ]
Gabra, Mohamed Diaa [2 ]
Nafady, Mohamed H. [3 ]
Elshawah, Hamza Emad [4 ]
Negida, Ahmed [5 ,6 ]
Mushtaq, Gohar [7 ]
Kamal, Mohammad Amjad [8 ,9 ,10 ,11 ]
机构
[1] Al Azhar Univ, Fac Med, Cairo, Egypt
[2] South Valley Univ, Fac Med, Qena, Egypt
[3] Misr Univ Sci & Technol, Fac Appl Med Sci, 6th October City, Egypt
[4] Al Azhar Univ, Fac Med, New Damietta, Egypt
[5] Zagazig Univ, Fac Med, Zagazig, Egypt
[6] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, England
[7] Idlib Univ, Fac Med, Ctr Sci Res, Idlib, Syria
[8] Sichuan Univ, West China Hosp, Inst Syst Genet, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China
[9] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah 21589, Saudi Arabia
[10] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka 1207, Bangladesh
[11] Enzymoics, Novel Global Community Educ Fdn, 7 Peterlee Pl, Hebersham, NSW 2770, Australia
关键词
Anti-inflammatory agents; immunosuppressive agents; immune modulators; colchicine; COVID-19; SARS-CoV-2; CORONAVIRUS; PROTEIN; ACE2;
D O I
10.2174/1381612827666211210142352
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current coronavirus disease (COVID-19) pandemic has affected millions of individuals worldwide. Despite extensive research efforts, few therapeutic options currently offer direct clinical benefits for COVID-19 patients. Despite the advances in our understanding of COVID-19, the mortality rates remain significantly high owing to the high viral transmission rates in several countries and the rise of various mutations in the SARS-CoV-2. One currently available and widely used drug that combines both anti-inflammatory and immunomodulatory actions is colchicine, which has been proposed as a possible treatment option for COVID-19. Colchicine still did not get much attention from the medical and scientific communities despite its anti-inflammatory and immunomodulatory mechanisms of action and positive preliminary data from early trials. This literature review article provides the scientific rationale for repurposing colchicine as a potential therapy for COVID-19. Further, we summarize colchicine's mechanisms of action and possible roles in COVID-19 patients. Finally, we supplement this review with a summary of the doses, side effects, and early efficacy data from clinical trials to date. Despite the promising early findings from multiple observational and clinical trials about the potential of colchicine in COVID-19, the data from the RECOVERY trial, the largest COVID-19 randomized controlled trial (RCT) in the world, showed no evidence of clinical benefits in mortality, hospital stays, or disease progression (n = 11340 patients). However, multiple other smaller clinical trials showed significant clinical benefits. We conclude that while current evidence does not support the use of colchicine for treating COVID-19, the present body of evidence is heterogeneous and inconclusive. The drug cannot be used in clinical practice or abandoned from clinical research without additional large RCTs providing more robust evidence. At present, the drug should not be used except for investigational purposes.
引用
收藏
页码:3194 / 3201
页数:8
相关论文
共 50 条
  • [31] Hypertension and COVID-19: Current Evidence and Perspectives
    Gallo, Giovanna
    Calvez, Valentin
    Savoia, Carmine
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2022, 29 (02) : 115 - 123
  • [32] Current evidence on the use of anakinra in COVID-19
    Khani, Elnaz
    Shahrabi, Marzieh
    Rezaei, Haleh
    Pourkarim, Fariba
    Afsharirad, Hoda
    Solduzian, Mohammad
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 111
  • [33] Hypertension and COVID-19: Current Evidence and Perspectives
    Giovanna Gallo
    Valentin Calvez
    Carmine Savoia
    High Blood Pressure & Cardiovascular Prevention, 2022, 29 : 115 - 123
  • [34] Understanding of COVID-19 based on current evidence
    Sun, Pengfei
    Lu, Xiaosheng
    Xu, Chao
    Sun, Wenjuan
    Pan, Bo
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (06) : 548 - 551
  • [35] Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review
    Mallet, Jasmina
    Dubertret, Caroline
    Le Strat, Yann
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2021, 106
  • [36] The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence
    Chatterjee, Pranab
    Nagi, Nazia
    Agarwal, Anup
    Das, Bhabatosh
    Banerjee, Sayantan
    Sarkar, Swarup
    Gupta, Nivedita
    Gangakhedkar, Raman R.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2020, 151 (2-3) : 147 - 159
  • [37] Use of therapeutic plasma exchange in COVID-19: A systematic review of current evidence
    Carlson, Nicholas
    Szpirt, Wladimir M.
    THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 : 3 - 11
  • [38] Cardiac complications during the active phase of COVID-19: review of the current evidence
    Mohammad Said Ramadan
    Lorenzo Bertolino
    Tommaso Marrazzo
    Maria Teresa Florio
    Emanuele Durante-Mangoni
    Internal and Emergency Medicine, 2021, 16 : 2051 - 2061
  • [39] Cardiac complications during the active phase of COVID-19: review of the current evidence
    Ramadan, Mohammad Said
    Bertolino, Lorenzo
    Marrazzo, Tommaso
    Florio, Maria Teresa
    Durante-Mangoni, Emanuele
    INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (08) : 2051 - 2061
  • [40] Return to Play Following COVID-19 Infection -A Systematic Review of Current Evidence
    Davey, Martin S.
    Davey, Matthew G.
    Hurley, Robert
    Hurley, Eoghan T.
    Pauzenberger, Leo
    JOURNAL OF SPORT REHABILITATION, 2022, 31 (02) : 218 - 223